National

India has been offered 7.5 million doses of Moderna vaccine

PTI New Delhi | Updated on July 20, 2021

Talks still on, no consensus yet on indemnity clause: sources

India has been offered 7.5 million doses of Moderna’s Covid-19 vaccine through the COVAX global vaccine sharing programme, but it is not clear when the jabs will arrive in the country as a consensus on the indemnity clause is yet to be reached, sources said.

The government last week said that it is working actively with vaccine manufacturer Moderna to see how its vaccine can be made available in the country.

Emergency use authorisation

Moderna’s Covid-19 vaccine was granted emergency use authorisation by India’s drug regulator last month.

Moderna’s Covid vaccine gets nod for restricted use

“India has been offered 7.5 million doses of Moderna’s Covid-19 vaccine through the COVAX global vaccine sharing programme,” the sources said.

However, there is no clarity so far when the shots would be available in India as “the talks are still on and a consensus on the indemnity issue is yet to be reached,” they said.

Close to commit over $1-b to Moderna for booster vaccine: Cipla to Govt

On the availability of Moderna vaccine in the country, NITI Aayog member (Health) Dr V K Paul had recently said the government is working actively with Moderna to see how its vaccine can be imported and made available in the country.

“...to and fro (talks) are going on over the contractual specifics. Discussions have not yet concluded. We are making efforts so it happens at the earliest. We are now expecting to hear from them anytime. Currently, they have to respond to some of the points we have made and we will take it forward,” he had said on Friday.

According to the sources, the Indian government has put forth certain conditions for finalising the indemnity clause contract and has sent it to the US drug manufacturer for their perusal.

Published on July 20, 2021

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor

You May Also Like